Patients Coming Off Weight-Loss Medications Put On Pounds at a Quadrupled Rate Compared to Those on Conventional Diets

Fresh analysis indicates that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop traditional lifestyle regimens.

Findings released in a prominent medical journal points out that while overweight people frequently drop about a fifth of their body weight while using the jabs, the mass returns at an average rate of nearly a kilo each month upon discontinuation.

"Users purchasing these treatments must be cognizant of the potential of fast rebound weight gain when the therapy ends," warns researcher Dr. Susan Jebb.

Such speed of recovery implies a return to starting weight in about one and a half years.

Comparing Therapies

The analysis, which reviewed dozens of trials involving over 9,000 of patients, compared the results of the injectable medications with conventional dieting.

Researchers point out that people who lose weight through dieting usually experience a slower creep back—approximately 100 grams monthly—after stopping.

Explaining the Fast Rebound

Doctors propose the way of the jabs accounts for the amplified regain.

GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.

"Long-term administration of the hormone levels several times higher than the body's typical production might result in the body to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.

"Stopping of this hormone supplement means appetite is unsuppressed, making binge eating much more probable."

An Ongoing Disease?

Health authorities suggest the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.

Many experts say that, considering the significant potential of relapse, the therapy should be considered life-long.

This perspective is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent character of obesity," comparing it to managing conditions like diabetes.

Patient Testimonies

Users who have come off the jabs explain a powerful resurgence of cravings.

"It felt as if something flipping and you're instantly starving," described one woman.

The struggle is exacerbated if users have not developed lasting dietary or behavioural changes during treatment.

Widespread Adoption

Recent estimates suggest that millions of adults in the UK have used these injections in the last 12 months, with demand continuing to grow.

• Use is greater among females compared to males.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion access the medications through private healthcare rather than the NHS.

In conclusion, researchers stress that while these medications are effective tools for shedding pounds, they are not a standalone fix and long-term success relies on ongoing behavioural management.